EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Cyclin-Dependent Kinases 4/6 Inhibition in Glioblastoma: From Molecular Rationale to Therapeutic Challenges and Opportunities

Ankush Chandra iD, Mariana K Najjar iD, Phi-Long Tran iD, Joshua Cha, Marc Morales, Hui-Wen Lo

Cancers · 06.11.2026 · 18 (21) · 3578

DOI: 10.3390/cancers18213578 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 06.11.2026. Verfasst von Ankush Chandra und 5 weiteren Autor:innen. Beteiligte Einrichtung: Vivian L. Smith Department of Neurosurgery, McGovern Medical School, The University of Texas Health Houston, Houston, TX 77030, USA. Die Arbeit nennt 127 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: United States Department of Defense, NIH HHS, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma (GBM) remains the most lethal primary malignant brain tumor in adults despite maximal resection, radiotherapy, and temozolomide. The cyclin D-CDK4/6-RB axis plays a significant role in cell cycle regulation and is amongst the most frequently dysregulated pathways in many cancers including GBM, thus providing a strong rationale for using CDK4/6 inhibitors (CDK4/6is) in treating this tumor. While palbociclib, ribociclib, and abemaciclib are FDA-approved to treat hormone positive breast cancer, they have demonstrated robust target engagement and efficacy in preclinical studies in GBM. However, clinical trial data has been modest, highlighting a major gap between biological rationale and therapeutic efficacy in the clinical setting. In this comprehensive review, we examine the molecular functions of CDK4/6 in GBM, delve into the pharmacologic properties of approved and emerging inhibitors, explore mechanisms of drug resistance and discuss combination strategies, clinical experience till date, and potential biomarkers for ideal patient selection. Future progress will likely require CNS-active inhibitors, rational combination therapies, functional biomarker selection, and early confirmation of adequate tumor drug exposure and pathway suppression.

Schlagwörter

Stichwörter der Autor:innen

CDK4CDK4/6 inhibitorCDK6combination therapycyclin-dependent kinasesglioblastomatargeted therapy

Autor:innen und Institutionen

  • Vivian L. Smith Department of Neurosurgery, McGovern Medical School, The University of Texas Health Houston, Houston, TX 77030, USA.
  • Department of Cell Biology and Genetics, College of Medicine, Texas A&M University, College Station, TX 77843, USA.
  • Graduate School of Biomedical Sciences, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA.
  • Department of Neurology, Virginia Tech Carilion, Roanoke, VA 24016, USA.

ORCID-Profile: Ankush Chandra, Mariana K Najjar, Phi-Long Tran

Förderung

  • United States Department of Defense
  • NIH HHS
  • NCI NIH HHS
  • METAvivor
  • NINDS NIH HHS
  • National Institutes of Health
  • Department of Defense

Zitieren

APA

Chandra, A., Najjar, M. K., Tran, P. L., Cha, J., Morales, M., & Lo, H. W. (2026). Cyclin-Dependent Kinases 4/6 Inhibition in Glioblastoma: From Molecular Rationale to Therapeutic Challenges and Opportunities. Cancers, 18(21), 3578. https://doi.org/10.3390/cancers18213578

Vancouver

Chandra A, Najjar MK, Tran PL, Cha J, Morales M, Lo HW. Cyclin-Dependent Kinases 4/6 Inhibition in Glioblastoma: From Molecular Rationale to Therapeutic Challenges and Opportunities. Cancers. 2026;18(21):3578. doi:10.3390/cancers18213578

BibTeX
@article{Chandra2026,
  author = {Chandra, Ankush and Najjar, Mariana K and Tran, Phi-Long and Cha, Joshua and Morales, Marc and Lo, Hui-Wen},
  title = {Cyclin-Dependent Kinases 4/6 Inhibition in Glioblastoma: From Molecular Rationale to Therapeutic Challenges and Opportunities},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {21},
  pages = {3578},
  doi = {10.3390/cancers18213578}
}
Kostenlos starten →